<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tropical pulmonary eosinophilia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tropical pulmonary eosinophilia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Tropical pulmonary eosinophilia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amy D Klion, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter F Weller, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 22, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Tropical pulmonary eosinophilia (TPE) is a clinical manifestation of lymphatic filariasis, a parasitic infection caused by filarial nematodes (roundworms) that inhabit the lymphatics and bloodstream. Three species cause human lymphatic filariasis: <em>Wuchereria bancrofti</em>, <em>Brugia malayi</em>, and <em>Brugia timori</em>. Infection is transmitted by mosquito vectors; humans are definitive hosts.</p><p>TPE is caused by an immune hyper-responsiveness to microfilariae trapped in the lungs [<a href="#rid1">1-4</a>]. The syndrome has also been termed tropical eosinophilia or tropical filarial pulmonary eosinophilia. Rarely, a similar hyper-responsive pulmonary syndrome can be seen in the setting of intestinal helminth infection [<a href="#rid5">5</a>].</p><p>Issues related to TPE of filarial origin will be reviewed here. Other issues related to lymphatic filariasis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5675.html" rel="external">"Lymphatic filariasis: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5680.html" rel="external">"Lymphatic filariasis: Treatment and prevention"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>TPE can occur in any tropical area where filariasis occurs and is most common among young adults. It is more common in individuals from the Indian subcontinent and occurs four to seven times more frequently in males than in females [<a href="#rid6">6,7</a>]. Rare cases have been described in children [<a href="#rid8">8</a>].</p><p>The majority of cases of TPE occur in endemic areas; cases in nonendemic settings have also been described. In a review of 17 cases observed in Toronto, all received an incorrect diagnosis at presentation (most often asthma), and a median of two consultations was required before the diagnosis was established [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H3733117"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Available evidence suggests that the pulmonary disease reflects a robust immunologic response against bloodborne microfilariae that become trapped within the lung and reticuloendothelial organs [<a href="#rid4">4</a>]. TPE develops in less than 0.5 percent of patients with lymphatic filariasis; the explanation for this observation remains unclear.</p><p>The earliest histopathologic finding is histiocytic infiltration [<a href="#rid6">6</a>]. Approximately one month following infection, an eosinophilic interstitial infiltrate develops. In more severe cases, eosinophilic abscesses, eosinophilic bronchopneumonia, or eosinophilic granulomas may be observed. With chronic disease, there is an ongoing eosinophil interstitial infiltration and increasing pulmonary fibrosis [<a href="#rid1">1</a>]. Occasionally, microfilarial fragments may be identifiable in biopsied lung or reticuloendothelial tissues [<a href="#rid6">6</a>].</p><p>A mouse model of TPE has been developed that recapitulates these findings [<a href="#rid10">10</a>]. In this model, rapid microfilarial clearance was accompanied by dramatic lung eosinophilia, local production of interleukin (IL-) 4, IL-5, and eotaxin, functional impairment of alveolar macrophages, activation of alternatively activated lung macrophages, and eosinophil upregulation of antiapoptotic genes. Subsequent data using the same model suggests that acidic calcium-independent phospholipase A2 plays a key role in this process [<a href="#rid11">11</a>]. </p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The onset of clinical manifestations is usually gradual. Symptoms include a dry, hacking, nonproductive cough, which is frequently paroxysmal and nocturnal. Asthma-like attacks are associated with breathlessness and wheezing. Other symptoms include weight loss, fatigue, and malaise. Dyspnea on exertion is relatively uncommon.</p><p>Chest findings are minimal or absent in most patients. In some cases, rhonchi, crepitations (especially over the midzones and bases), and wheezing may be auscultated. Lymphadenopathy, hepatomegaly, and/or splenomegaly are observed in approximately 15 percent of patients [<a href="#rid6">6</a>]. Cor pulmonale is a rare complication [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H4"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The cardinal laboratory finding in TPE is blood eosinophilia, usually above 3000/microL [<a href="#rid7">7</a>]. An elevation in serum immunoglobulin E level is frequently observed, often above 1000 units/mL. The diagnosis can be confirmed by marked elevations in filarial antibody titers. Microfilariae are generally not detectable in peripheral blood, and circulating filarial antigen is undetectable in up to 50 percent of cases [<a href="#rid13">13</a>]. Bronchoalveolar lavage reveals an intense eosinophilic alveolitis in patients with active disease [<a href="#rid3">3</a>]. </p><p>The major chest radiograph findings include increased bronchoalveolar markings, diffuse interstitial lesions (1 to 3 mm in diameter), and/or mottled opacities (usually most prominent in the lower lung fields) (<a class="graphic graphic_diagnosticimage graphicRef75859" href="/z/d/graphic/75859.html" rel="external">image 1</a>). Hilar lymphadenopathy and pleural effusions are rare. The chest radiograph is normal in 20 to 30 percent of cases [<a href="#rid6">6</a>]. High-resolution computed tomography can be useful and typically shows widespread ill-defined bronchocentric nodules and ground-glass infiltrates, although these findings are not specific for TPE and can occur in other types of inflammatory and infectious pneumonitis [<a href="#rid14">14</a>]. </p><p>Pulmonary function tests (PFTs) typically demonstrate a predominantly restrictive pattern together with mild to moderate airway obstruction. In some cases, PFTs demonstrate a predominantly obstructive pattern with a mild restrictive component [<a href="#rid6">6</a>]. Airway obstruction is reversible with bronchodilators.</p><p class="headingAnchor" id="H8335358"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of TPE includes chronic eosinophilic pneumonia, drug hypersensitivity reactions, fungal pneumonia, and pulmonary syndromes associated with other helminths (most commonly <em>Toxocara</em> hookworm, <em>Ascaris</em>, and <em>Strongyloides</em>) [<a href="#rid5">5</a>]. Among these, strongyloidiasis is most important to exclude since corticosteroid administration can lead to fatal dissemination of infection. Although the imaging studies in TPE can mimic miliary tuberculosis [<a href="#rid15">15</a>], the presence of marked eosinophilia in TPE is an important distinguishing feature. (See related topics.)</p><p class="headingAnchor" id="H7"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Standard treatment consists of <a class="drug drug_general" data-topicid="112050" href="/z/d/drug information/112050.html" rel="external">diethylcarbamazine</a> (DEC) given at 6 mg/kg/day in three doses for 12 to 21 days [<a href="#rid16">16,17</a>]. DEC is active against both the microfilariae and adult worms, and DEC therapy is associated with a dramatic and rapid improvement in signs and symptoms in most cases. The restrictive and obstructive defects typically return toward normal if DEC is administered in the first few years of disease, although a low-grade eosinophilic alveolitis may persist [<a href="#rid18">18</a>]. If DEC therapy is delayed, progressive interstitial fibrosis and irreversible impairment in pulmonary function can occur.</p><p>Corticosteroid therapy has been used as adjunctive therapy to reduce inflammation in the acute setting but is not definitive therapy for TPE.</p><p>Relapses occur in up to 20 percent of patients within the first five years of DEC therapy [<a href="#rid6">6</a>] and are treated with a repeat course of the same treatment regimen.</p><p>Other agents are used in the treatment of lymphatic filariasis, including <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (which has efficacy against adult filarial worms via its action on their <em>Wolbachia</em> endosymbionts [<a href="#rid18">18</a>]), <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a> (a rapid microfilaricide without efficacy on adult worms), and <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> (which affects only adult worms). However, there are no published data describing any of these as either primary or adjunctive treatment for TPE.</p><p>Bronchospasm can generally be managed with bronchodilators, although short-term corticosteroids may be necessary in severe cases. (See  <a class="medical medical_review" href="/z/d/html/5680.html" rel="external">"Lymphatic filariasis: Treatment and prevention", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management"</a>.)</p><p>DEC is not distributed for use in the United States but can be obtained from the Centers for Disease Control and Prevention under an Investigational New Drug protocol (CDC Drug Service, Atlanta, GA 30333; telephone 404-639-2888). (See  <a class="medical medical_review" href="/z/d/html/5680.html" rel="external">"Lymphatic filariasis: Treatment and prevention", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H3037715"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Tropical pulmonary eosinophilia (TPE) is a clinical manifestation of lymphatic filariasis, a parasitic infection caused by nematodes (roundworms) that inhabit the lymphatics and bloodstream. TPE is caused by an immune hyper-responsiveness to microfilariae that become trapped in the lungs. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TPE can occur in any tropical area where filariasis occurs and is most common among young adults. It is more common in individuals from the Indian subcontinent and occurs four to seven times more frequently in males than in females. Rarely, a similar hyper-responsive pulmonary syndrome can occur in the setting of other helminth infections. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The onset of clinical manifestations is usually gradual. Symptoms include a dry, hacking, nonproductive cough that is frequently paroxysmal and nocturnal. Asthma-like attacks are associated with breathlessness and wheezing. Other symptoms include weight loss, fatigue, and malaise. Dyspnea on exertion is relatively uncommon. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The cardinal laboratory finding in TPE is blood eosinophilia, usually above 3000/microL. An elevation in serum immunoglobulin E level is frequently observed, often above 1000 units/mL. Chest radiographic studies typically show widespread ill-defined bronchocentric nodules and ground-glass infiltrates, although mediastinal lymphadenopathy and pleural effusions have been described. The diagnosis can be confirmed by elevations in filarial antibody titers. Microfilariae are generally not detectable in peripheral blood. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For treatment of TPE, we recommend <a class="drug drug_general" data-topicid="112050" href="/z/d/drug information/112050.html" rel="external">diethylcarbamazine</a> (6 mg/kg/day in three doses for 12 to 21 days) (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Bronchospasm can be managed with bronchodilators and, in severe cases, short-term corticosteroids. (See <a class="local">'Treatment'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Vijayan VK. Tropical pulmonary eosinophilia: pathogenesis, diagnosis and management. Curr Opin Pulm Med 2007; 13:428.</a></li><li><a class="nounderline abstract_t">Weingarten RJ. Tropical eosinophilia. Lancet 1943; 1:103.</a></li><li><a class="nounderline abstract_t">Pinkston P, Vijayan VK, Nutman TB, et al. Acute tropical pulmonary eosinophilia. Characterization of the lower respiratory tract inflammation and its response to therapy. J Clin Invest 1987; 80:216.</a></li><li><a class="nounderline abstract_t">Ottesen EA, Nutman TB. Tropical pulmonary eosinophilia. Annu Rev Med 1992; 43:417.</a></li><li><a class="nounderline abstract_t">Rocha A, Dreyer G, Poindexter RW, Ottesen EA. Syndrome resembling tropical pulmonary eosinophilia but of non-filarial aetiology: serological findings with filarial antigens. Trans R Soc Trop Med Hyg 1995; 89:573.</a></li><li class="breakAll">Udwadia FE. Tropical eosinophilia. In: Progress in Respiration Research: Pulmonary Eosinophilia, Udwadia FE (Ed), Karger, New York 1975. p.35.</li><li><a class="nounderline abstract_t">Ong RK, Doyle RL. Tropical pulmonary eosinophilia. Chest 1998; 113:1673.</a></li><li><a class="nounderline abstract_t">Randev S, Kumar P, Dhillon P, et al. Tropical pulmonary eosinophilia masquerading as asthma in a 5-year-old girl. Paediatr Int Child Health 2018; 38:231.</a></li><li><a class="nounderline abstract_t">Boggild AK, Keystone JS, Kain KC. Tropical pulmonary eosinophilia: a case series in a setting of nonendemicity. Clin Infect Dis 2004; 39:1123.</a></li><li><a class="nounderline abstract_t">Sharma P, Sharma A, Vishwakarma AL, et al. Host lung immunity is severely compromised during tropical pulmonary eosinophilia: role of lung eosinophils and macrophages. J Leukoc Biol 2016; 99:619.</a></li><li><a class="nounderline abstract_t">Sharma P, Sharma A, Ganga L, et al. Acidic Calcium-Independent Phospholipase A2 Regulates Eosinophil-Mediated Pathology during Filarial Manifestation of Tropical Pulmonary Eosinophilia. J Immunol 2021; 206:722.</a></li><li><a class="nounderline abstract_t">Tsanglao WR, Nandan D, Chandelia S, et al. Filarial tropical pulmonary eosinophilia: a condition masquerading asthma, a series of 12 cases. J Asthma 2019; 56:791.</a></li><li><a class="nounderline abstract_t">Lal RB, Paranjape RS, Briles DE, et al. Circulating parasite antigen(s) in lymphatic filariasis: use of monoclonal antibodies to phosphocholine for immunodiagnosis. J Immunol 1987; 138:3454.</a></li><li><a class="nounderline abstract_t">Angirish B, Jankharia B, Sanghavi P. The role of HRCT in Tropical Pulmonary Eosinophilia. Eur J Radiol 2020; 131:109207.</a></li><li><a class="nounderline abstract_t">Ray S, Kundu S, Goswami M, Maitra S. Tropical pulmonary eosinophilia misdiagnosed as miliary tuberculosis: a case report and literature review. Parasitol Int 2012; 61:381.</a></li><li class="breakAll">Drugs for Parasitic Infections, 3rd ed, The Medical Letter, New Rochelle, NY 2013.</li><li><a class="nounderline abstract_t">Fernando SD, Rodrigo C, Rajapakse S. Current evidence on the use of antifilarial agents in the management of bancroftian filariasis. J Trop Med 2011; 2011:175941.</a></li><li><a class="nounderline abstract_t">Hoerauf A. Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis. Curr Opin Infect Dis 2008; 21:673.</a></li></ol></div><div id="topicVersionRevision">Topic 5711 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17940489" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Tropical pulmonary eosinophilia: pathogenesis, diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Tropical eosinophilia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3298321" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Acute tropical pulmonary eosinophilia. Characterization of the lower respiratory tract inflammation and its response to therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1580599" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Tropical pulmonary eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8560543" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Syndrome resembling tropical pulmonary eosinophilia but of non-filarial aetiology: serological findings with filarial antigens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8560543" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Syndrome resembling tropical pulmonary eosinophilia but of non-filarial aetiology: serological findings with filarial antigens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9631810" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Tropical pulmonary eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28488945" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Tropical pulmonary eosinophilia masquerading as asthma in a 5-year-old girl.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15486834" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Tropical pulmonary eosinophilia: a case series in a setting of nonendemicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26489428" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Host lung immunity is severely compromised during tropical pulmonary eosinophilia: role of lung eosinophils and macrophages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33441441" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Acidic Calcium-Independent Phospholipase A2 Regulates Eosinophil-Mediated Pathology during Filarial Manifestation of Tropical Pulmonary Eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29969926" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Filarial tropical pulmonary eosinophilia: a condition masquerading asthma, a series of 12 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2437195" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Circulating parasite antigen(s) in lymphatic filariasis: use of monoclonal antibodies to phosphocholine for immunodiagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32823149" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The role of HRCT in Tropical Pulmonary Eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22172479" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Tropical pulmonary eosinophilia misdiagnosed as miliary tuberculosis: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22172479" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Tropical pulmonary eosinophilia misdiagnosed as miliary tuberculosis: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21234244" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Current evidence on the use of antifilarial agents in the management of bancroftian filariasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18978537" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
